{"id":9714,"date":"2026-03-25T16:42:45","date_gmt":"2026-03-25T08:42:45","guid":{"rendered":"https:\/\/regask.com\/?p=9714"},"modified":"2026-03-25T16:43:42","modified_gmt":"2026-03-25T08:43:42","slug":"die-fda-fuhrt-ein-einheitliches-system-zur-uberwachung-unerwunschter-ereignisse-aems-ein-um-die-meldung-von-sicherheitsvorfallen-nach-der-markteinfuhrung-zu-vereinfachen","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/","title":{"rendered":"FDA f\u00fchrt einheitliches System zur \u00dcberwachung unerw\u00fcnschter Ereignisse ein (A\u2026"},"content":{"rendered":"<p>An <strong>11. M\u00e4rz 2026<\/strong>, Die <strong>US-amerikanische Food and Drug Administration (FDA)<\/strong> startete die <strong>System zur \u00dcberwachung unerw\u00fcnschter Ereignisse (AEMS)<\/strong>, eine einheitliche Plattform zur Verbesserung <strong>Datenmanagement zur Sicherheit nach der Markteinf\u00fchrung<\/strong> Das System deckt alle FDA-regulierten Produktkategorien ab und konsolidiert mehrere \u00e4ltere Datenbanken in einer einzigen Datenbank. <strong>einheitliches Echtzeit-Berichts-Dashboard<\/strong>, mit einer schrittweisen Migration und Systemstilllegung, die \u00fcber <strong>Mai 2026<\/strong>.<\/p>\n<div class=\"row\"  id=\"row-1796003016\">\n\n\t<div id=\"col-322973315\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-764936588\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-764936588 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Details zum Update<\/h2>\n\t<div id=\"gap-1941487495\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1941487495 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Die neu eingef\u00fchrt <strong>AEMS<\/strong> ersetzt mehrere \u00e4ltere Systeme zur Meldung unerw\u00fcnschter Ereignisse, darunter <strong>FAERS<\/strong>, <strong>VAERS<\/strong>, <strong>AERS<\/strong>, <strong>MAUDE<\/strong>, <strong>HFCS<\/strong>, Und <strong>CTPAE<\/strong>, wodurch die gesamte Berichterstattung in eine <strong>zentrale Plattform<\/strong>. Diese Konsolidierung erm\u00f6glicht <strong>Echtzeitver\u00f6ffentlichung von Berichten \u00fcber unerw\u00fcnschte Ereignisse<\/strong> \u00fcber Produktkategorien hinweg, wie beispielsweise Arzneimittel, Biologika, Impfstoffe, Kosmetika, Medizinprodukte, Lebensmittel f\u00fcr den menschlichen Verzehr, Nahrungserg\u00e4nzungsmittel, Tierfutter und Tabakwaren.<\/p>\n<p>Die Plattform stellt vor <strong>verbesserte APIs und Analysetools<\/strong>, was eine verbesserte <strong>Datenzugriff und Integration<\/strong> f\u00fcr regulatorische, Qualit\u00e4ts- und Sicherheitsfunktionen. Diese Funktionen sollen eine effizientere \u00dcberwachung, Signalerkennung und Einhaltungsnachverfolgung unterst\u00fctzen.<\/p>\n<p>Historische Daten aus Altsystemen werden <strong>Migration zu AEMS<\/strong>, mit <strong>schrittweise Stilllegung<\/strong> von fr\u00fcheren Plattformen, die im Zuge der Migration auftreten. Durch die <strong>Ende Mai 2026<\/strong>, Es wird erwartet, dass AEMS als die <strong>prim\u00e4res System zur Meldung und Sichtbarkeit unerw\u00fcnschter Ereignisse<\/strong> in allen von der FDA regulierten Sektoren.<\/p>\n<p>Interessengruppen, einschlie\u00dflich <strong>Hersteller, medizinisches Fachpersonal und Patientensicherheitsteams<\/strong>, Sie m\u00fcssen ihre Berichtsprozesse w\u00e4hrend der \u00dcbergangszeit an die neuen Systemanforderungen anpassen.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-322973315 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-648576874\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Fristen<\/h2>\n\t<div id=\"gap-1264097035\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1264097035 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Der <strong>Die AEMS-Plattform wurde am 11. M\u00e4rz 2026 eingef\u00fchrt.<\/strong>, mit <strong>schrittweise Migration und Stilllegung<\/strong> von Altsystemen, deren Fertigstellung bis zum erwartet wird <strong>Ende Mai 2026<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-648576874 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1339751194\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Warum es wichtig ist<\/h2>\n\t<div id=\"gap-715199932\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-715199932 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Dieses Update verbessert <strong>Transparenz und Effizienz<\/strong> in der \u00dcberwachung der Arzneimittelsicherheit nach der Markteinf\u00fchrung durch die Erm\u00f6glichung <strong>Echtzeitzugriff auf Daten zu unerw\u00fcnschten Ereignissen<\/strong> \u00fcber alle Produktkategorien hinweg. Das zentralisierte System unterst\u00fctzt <strong>digitale Integration<\/strong>, verbessert <strong>regulatorische Aufsicht<\/strong>, und optimiert <strong>Datenverwaltungsprozesse<\/strong>, wodurch die Fragmentierung verringert und die Konsistenz der Sicherheitsberichterstattung verbessert wird.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1339751194 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1865150872\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Wen das betrifft<\/h2>\n\t<div id=\"gap-634725762\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-634725762 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Dieses Update ist relevant f\u00fcr <strong>Regulatorische Angelegenheiten<\/strong>, <strong>Qualit\u00e4tssicherung<\/strong>, <strong>Patientensicherheit<\/strong>, Und <strong>Pharmakovigilanz-Teams<\/strong> organisations\u00fcbergreifendes Marketing <strong>FDA-regulierte Produkte<\/strong>, einschlie\u00dflich Arzneimittel, Biologika, Medizinprodukte, Lebensmittel und Tabakwaren.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1865150872 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1688975351\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>N\u00e4chste Schritte<\/h2>\n\t<div id=\"gap-1100381642\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1100381642 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Organisationen sollten <strong>Bewertung der aktuellen Arbeitsabl\u00e4ufe zur Meldung unerw\u00fcnschter Ereignisse<\/strong> und sicherstellen <strong>Systemkompatibilit\u00e4t mit AEMS-Anforderungen<\/strong>. Funktions\u00fcbergreifende Teams sollten zusammenarbeiten, um <strong>Aktualisierung interner Protokolle<\/strong>, ausrichten <strong>Datenintegrationsprozesse<\/strong>, und bereiten Sie sich vor auf <strong>Echtzeitberichterstattung und -\u00fcberwachung<\/strong> im Zuge der schrittweisen Migration.<\/p>\n<p>Da die globalen Regulierungsbeh\u00f6rden die Sicherheits\u00fcberwachungssysteme kontinuierlich modernisieren, ist die Aufrechterhaltung der \u00dcbereinstimmung mit den sich entwickelnden Meldeinfrastrukturen von entscheidender Bedeutung f\u00fcr die Einhaltung der Vorschriften und das Risikomanagement.<\/p>\n<p><a href=\"https:\/\/regask.com\/de\/\">RegASK<\/a> ist eine f\u00fchrende agentenbasierte KI-Plattform f\u00fcr regulatorische Analysen und Workflow-Orchestrierung, die globale Unternehmen in stark regulierten Branchen wie Konsumg\u00fcter und Life Sciences dabei unterst\u00fctzt, sich proaktiv in komplexen regulatorischen Umfeldern zu bewegen. Durch die Kombination von fortschrittlicher agentenbasierter KI mit Expertenwissen, <a href=\"https:\/\/regask.com\/de\/\">RegASK<\/a> liefert zeitnahe, vorausschauende und umsetzbare Erkenntnisse sowie eine durchg\u00e4ngige Automatisierung, optimiert Compliance-Prozesse, mindert Risiken und beschleunigt den Marktzugang in mehr als 160 L\u00e4ndern. <a href=\"https:\/\/regask.com\/de\/produkt\/\">Mehr erfahren<\/a> oder <a href=\"https:\/\/regask.com\/de\/demo-buchen\/\">Demo buchen<\/a> Jetzt.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1688975351 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1367390913\">\n\n\t<div id=\"col-922476798\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQs<\/h3>\n\t<div id=\"gap-299847548\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-299847548 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>Was ist das FDA-System zur \u00dcberwachung unerw\u00fcnschter Ereignisse (AEMS)?<\/h4>\n\t<div id=\"gap-1807680614\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1807680614 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>es ist ein <strong>zentrale Plattform<\/strong> f\u00fcr <strong>Echtzeit-Meldung und \u00dcberwachung unerw\u00fcnschter Ereignisse<\/strong> \u00fcber alle von der FDA regulierten Produktkategorien hinweg.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-922476798 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1524718942\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Welche Systeme werden durch AEMS ersetzt?<\/h4>\n\t<div id=\"gap-1861853920\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1861853920 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>AEMS ersetzt <strong>FAERS<\/strong>, <strong>VAERS<\/strong>, <strong>AERS<\/strong>, <strong>MAUDE<\/strong>, <strong>HFCS<\/strong>, Und <strong>CTPAE<\/strong>, und sie in einem einzigen System zusammenzuf\u00fchren.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1524718942 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2033365910\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Wann wird die Umstellung auf AEMS abgeschlossen sein?<\/h4>\n\t<div id=\"gap-557530984\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-557530984 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Der <strong>schrittweise Migration und Stilllegung<\/strong> Die Modernisierung der Altsysteme wird voraussichtlich bis zum [Datum einf\u00fcgen] abgeschlossen sein. <strong>Ende Mai 2026<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2033365910 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1049708684\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Wie kann RegASK Organisationen bei der Anpassung an AEMS unterst\u00fctzen?<\/h4>\n\t<div id=\"gap-296567113\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-296567113 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"http:\/\/regask.com\/de\/\">RegASK <\/a>hilft Organisationen <strong>\u00c4nderungen des Regulierungssystems verfolgen<\/strong>, ausrichten <strong>Berichts-Workflows<\/strong>, und optimieren <strong>Compliance-Prozesse<\/strong>, um eine nahtlose Anpassung an neue Anforderungen an die Sicherheits\u00fcberwachung zu gew\u00e4hrleisten.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1049708684 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched the Adverse Event Monitoring System (AEMS), a unified platform designed to enhance postmarket safety data management across all FDA-regulated product categories. The system consolidates multiple legacy databases into a single real-time reporting dashboard, with phased migration and system decommissioning scheduled through May 2026.<\/p>","protected":false},"author":32,"featured_media":9715,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33],"tags":[],"class_list":["post-9714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Launches Unified Adverse Event Monitoring System Overview<\/title>\n<meta name=\"description\" content=\"The FDA launches a unified adverse event monitoring system to enhance postmarket safety reporting for all regulated products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/die-fda-fuhrt-ein-einheitliches-system-zur-uberwachung-unerwunschter-ereignisse-aems-ein-um-die-meldung-von-sicherheitsvorfallen-nach-der-markteinfuhrung-zu-vereinfachen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Launches Unified Adverse Event Monitoring System (AEMS) to Streamline Postmarket Safety Reporting\" \/>\n<meta property=\"og:description\" content=\"The FDA launches a unified adverse event monitoring system to enhance postmarket safety reporting for all regulated products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/die-fda-fuhrt-ein-einheitliches-system-zur-uberwachung-unerwunschter-ereignisse-aems-ein-um-die-meldung-von-sicherheitsvorfallen-nach-der-markteinfuhrung-zu-vereinfachen\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T08:42:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T08:43:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hannah Nordin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hannah Nordin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/\"},\"author\":{\"name\":\"Hannah Nordin\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\"},\"headline\":\"FDA Launches Unified Adverse Event Monitoring System (A&hellip;\",\"datePublished\":\"2026-03-25T08:42:45+00:00\",\"dateModified\":\"2026-03-25T08:43:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/\"},\"wordCount\":734,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"articleSection\":[\"Regulatory News\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/\",\"name\":\"FDA Launches Unified Adverse Event Monitoring System Overview\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"datePublished\":\"2026-03-25T08:42:45+00:00\",\"dateModified\":\"2026-03-25T08:43:42+00:00\",\"description\":\"The FDA launches a unified adverse event monitoring system to enhance postmarket safety reporting for all regulated products.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"width\":800,\"height\":600,\"caption\":\"Fda Launches Unified Adverse Event Monitoring System Aems Streamline Postmarket Safety Reporting\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\",\"name\":\"Hannah Nordin\",\"sameAs\":[\"https:\\\/\\\/regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA f\u00fchrt einheitliches System zur \u00dcberwachung unerw\u00fcnschter Ereignisse ein \u2013 \u00dcberblick","description":"Die FDA f\u00fchrt ein einheitliches System zur \u00dcberwachung unerw\u00fcnschter Ereignisse ein, um die Meldung von Sicherheitsvorf\u00e4llen nach der Markteinf\u00fchrung f\u00fcr alle regulierten Produkte zu verbessern.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/die-fda-fuhrt-ein-einheitliches-system-zur-uberwachung-unerwunschter-ereignisse-aems-ein-um-die-meldung-von-sicherheitsvorfallen-nach-der-markteinfuhrung-zu-vereinfachen\/","og_locale":"de_DE","og_type":"article","og_title":"FDA Launches Unified Adverse Event Monitoring System (AEMS) to Streamline Postmarket Safety Reporting","og_description":"The FDA launches a unified adverse event monitoring system to enhance postmarket safety reporting for all regulated products.","og_url":"https:\/\/regask.com\/de\/die-fda-fuhrt-ein-einheitliches-system-zur-uberwachung-unerwunschter-ereignisse-aems-ein-um-die-meldung-von-sicherheitsvorfallen-nach-der-markteinfuhrung-zu-vereinfachen\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-25T08:42:45+00:00","article_modified_time":"2026-03-25T08:43:42+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","type":"image\/png"}],"author":"Hannah Nordin","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Hannah Nordin","Est. reading time":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/#article","isPartOf":{"@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/"},"author":{"name":"Hannah Nordin","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65"},"headline":"FDA Launches Unified Adverse Event Monitoring System (A&hellip;","datePublished":"2026-03-25T08:42:45+00:00","dateModified":"2026-03-25T08:43:42+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/"},"wordCount":734,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","articleSection":["Regulatory News"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/","url":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/","name":"FDA f\u00fchrt einheitliches System zur \u00dcberwachung unerw\u00fcnschter Ereignisse ein \u2013 \u00dcberblick","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","datePublished":"2026-03-25T08:42:45+00:00","dateModified":"2026-03-25T08:43:42+00:00","description":"Die FDA f\u00fchrt ein einheitliches System zur \u00dcberwachung unerw\u00fcnschter Ereignisse ein, um die Meldung von Sicherheitsvorf\u00e4llen nach der Markteinf\u00fchrung f\u00fcr alle regulierten Produkte zu verbessern.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/fda-launches-unified-adverse-event-monitoring-system-aems-to-streamline-postmarket-safety-reporting\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","width":800,"height":600,"caption":"Fda Launches Unified Adverse Event Monitoring System Aems Streamline Postmarket Safety Reporting"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Intelligentere Regulierungsentscheidungen erm\u00f6glichen","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65","name":"Hannah Nordin","sameAs":["https:\/\/regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/9714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=9714"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/9714\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/9715"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=9714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=9714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=9714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}